Advanced Enzyme Technologies Ltd - 540025 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 Advanced Enzyme Technologies Ltd - 540025 - Announcement under Regulation 30 (LODR)-Change in Directorate
Mr. Kedar Desai , Independent Director, will cease to be the Director of the Company with effect from March 31, 2024 (end of business hours) due to completion of his second term of five years as an Independent Director. Advanced Enzyme Technologies Ltd - 540025 - Closure of Trading Window
Pursuant to the provisions of the Insider Trading Code of the Company read with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015, (as amended), the "Trading Window" for trading in securities of the Company shall remain closed from April 01, 2024 (Monday) till 48 Hours after the commencement of the Company''s financial results for the quarter and year ended March 31, 2024. Advanced Enzyme Technologies Ltd - 540025 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Advanced Enzyme Technologies Limited has informed the Exchange about Schedule of meet - Kayne Anderson Rudnick, US Advanced Enzyme Technologies Ltd - 540025 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Advanced Enzyme Technologies Limited has informed the Exchange about Schedule of meet - Aurigin Capital Management, Singapore, Polar Capital Partners, London and UTI MF Advanced Enzyme Technologies Ltd - 540025 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Advanced Enzyme Technologies Limited has informed the Exchange about Schedule of meet - Clarus Capital 1, Securities Investment Management Pvt Ltd , Tamohara Investment Managers and Banyan Tree Advisors Advanced Enzyme Technologies Ltd - 540025 - Update On Acquisition Of Additional Stake Of 5.89% In JC Biotech Private Limited, Subsidiary I.E. Increase In Shareholding From 89.83% To 95.72%
Further to our letter dated February 10, 2024, we would like to inform that the Company has completed the acquistion of additional stake of 5.89% in JC Biotech Private Limited, subsidiary ["JCB"] by way of purchase of 12,18,976 Equity Shares from few selling shareholders of JCB, for a consideration of Rs. 56.07 million i.e. Rs. 46 per Equity Share. In View of this, the shareholding of the Company in JCB has increased from 89.83% to 95.72% of paid-up share capital of JCB. Advanced Enzyme Technologies Ltd - 540025 - Order Pertaining To The Judicial Proceedings Against Advanced Supplementary Technologies Corporation, USA (Step Down Wholly Owned Subsidiary) ['AST']
Order Pertaining to the judicial proceedings against Advanced Supplementary Technologies Corporation, USA (Step down wholly owned subsidiary)["AST"] Advanced Enzyme Technologies Ltd - 540025 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Advanced Vital Enzymes Pvt Ltd Advanced Enzyme Technologies Ltd - 540025 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
In furtherance to our intimation letter dated February 10, 2024, please find enclosed the Transcript of the Conference call held on Friday, February 16, 2024 with Analysts and Investors for the un-audited Financial Results of the Company for the quarter and nine months ended December 31, 2023